Latin America Cytokine Based Therapies And Inhibitors Market

The size of the Latin American Cytokine Based Therapies and Inhibitors Market is estimated to hike at a steady rate from 2022 to 2027.

Cytokines are molecular messengers that allow immune system cells to communicate with each other to generate a coordinated, robust but self-limited response to a target antigen. Hence, the demand for cytokine-based therapies and inhibitors is analyzed to increase with the increase in cancer incidence in the future. According to the recent report, the cancer incidence and population growth are consistent. They will reach over 27.52 million new cancer cases worldwide each year by 2040, up from 17 million reported cases in 2018. Recent technology developments have given rise to the different cytokines used to treat cancer patients, namely interferons (INF), interleukins (IL), and hematopoietic growth factors.

Researchers are focusing on producing novel therapies with minimal side-effects such as target inflammatory cytokines by focusing on anti-TNF antibodies or recombinant TNF decoy receptor, recombinant IL-1 receptor antagonist, and anti-IL-1 antibodies. These are target modes of action due to specific proteins involved in inflammatory activity.

The rapid increase in the number of patients suffering from cytokine storms is also driving the market growth rate in Latin America. It is a life-threatening condition triggered by viral infections like COVID-19 infections. Numerous cytokine storm-induced consequences can occur during this infection, including pulmonary fibrosis, acute respiratory distress syndrome, and multi-organ failure, eventually leading to patient death. These can be confirmed by a bilateral vitreous appearance on a CT scan. To relieve symptoms, it is vital to effectively and quickly inhibit the cytokine storm using modified QTY proteins, which bind the excess cytokines generated by the cytokine storm, thus preventing complications. All these factors are expected to favor the market's growth rate during the forecast period.

However, market growth is limited for cytokine therapies, and inhibitors as cytokines can cause redundancy resulting in weak immunity in the body. Other factors that may slow down the studied market are lack of skilled labor and limited use in patients.

This research report on the Latin America cytokine-based therapies and inhibitors market has been segmented and sub-segmented into the following categories.

By Type:

• Interleukins            
• Tumor necrosis factor        
• Epidermal growth factor   
• Interferon               
• Chemokine    

By Therapeutic Application:

• Inflammatory and immune disorders          
• Cancer and malignancies   
• Infectious diseases              
• Others

By Country:

• Mexico
• Brazil
• Argentina
• Chile
• Rest of Latin America

In 2022, the regional market in Brazil accounted for the most significant market growth. This dominant market share can be attributed to the considerable growth in the pharmaceutical industry, high prevalence of diseases, increase in the number of clinics, researchers who are focusing on the development of novel therapies and inhibitors, which in turn will increase the demand for cytokine therapies and the market inhibitors in Brazil. Furthermore, with the advancement of biotechnological techniques and knowledge about the expression and isolation of highly purified recombinant proteins, the market aims to produce ease of use and cheaper products. As a result, in 2020, approximately 19.32 million new cases of cancer and nearly 10.41 million cancer deaths had arisen due to the increasing adoption of cytokine-based therapies and inhibitors.

Increased research and development activities have been noted in Latin American regions, boosting the market growth. Brazil, Argentina, and Colombia concentrated on the highest number of trials, with 45.9%, 14.9%, and 9.7%. While in South and Central America, over 212% increase in the number of clinical trials was reported.

KEY MARKET PLAYERS:

Some of the significant players in the Cytokine Based Therapies and Inhibitors market are GlaxoSmithKline LLC, AbbVie Inc., Eli Lilly and Company, Genentech, Inc., Immunochemistry Technologies LLC, Roche Diagnostics, Novartis, Merck Sharp & Dohme Corp., Johnson & Johnson, and Amgen Inc.